Grin Therapeutics Inc.

2 trials 1 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

8 Countries active

1 Unique IMPs

100% Results reported

Phase III

Phase I/II

Phase III: 1 Phase I/II: 1

Oversight events:

1 urgent safety measure 1 corrective measure across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Neurodevelopmental disorder 1 Tuberous sclerosis complex 1

Top IMPs

All trials

2 total

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Ope… Recruiting

2023-509672-42-00 Phase III 8 countries RADIPRODIL
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi… Ended

2023-506301-20-00 Phase I/II 5 countries RADIPRODIL

Showing 1–2 of 2 trials

← All sponsors A–Z